RCKT Q1 2024 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$2M

Operating Income

-$67M

Net Income

-$62M

EPS (Diluted)

$-0.66

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$59M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$499M

Total Liabilities

$58M

Stockholders' Equity

$442M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$2M	$0	—
Operating Income	-$67M	-$62M	-8.3%
Net Income	-$62M	-$58M	-6.4%